Mabwell
68806228.554.96% ( -1.49 )
Mabwell (688062)
Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological...
- Open
- 29.93
- High
- 30.37
- Low
- 28.38
- Prev. Close
- 30.04
- Volume
- 91.09K
- Turnover
- 265.86M
- Avg Price
- 29.19
- Bid/Ask Ratio
- --
- Amplitude
- 6.62%
- 52wk High
- 63.59
- Volume Ratio
- 0.67
- Turnover Ratio
- 3.96%
Mabwell Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
¥54.7091.59%
Forecast & RatingStrong buy
3analysts
- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 15 at 07:03 AM
Mabwell says China NMPA clears 9MW5211 vitiligo trial application
- PUBT · Jun 23 at 07:00 PM
Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancers
- Tip Ranks · Jun 18 at 09:43 AM
Mabwell Showcases Promising Nectin-4 ADC Data in Cervical Cancer at ESMO Gynae 2026
- 同壁财经 · Jun 3 at 05:40 AM
Mabwell's ESG rating upgraded to A, with a composite score of 7.28, leading the pharmaceutical industry rating
- prnewswire · May 21 at 10:32 PM
23:30 ETMabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentations
- Tip Ranks · May 20 at 10:09 AM
Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates
